Agenus has pushed BOT plus BAL into a global Phase 3 colorectal cancer trial and is generating early access revenue, but the current thesis is a race between regulatory progress and financing pressure: Q1 cash was $35.0M, operating cash flow was negative, the latest 10-Q carries going-concern language, and the products remain investigational.
References
Sources used in this report
SEC datasetSEC company tickers exchange dataset2026-05-14 · Issuer name, ticker, CIK and Nasdaq listing confirmation.SEC APISEC submissions for Agenus2026-05-14 · Filing chronology, latest 10-K, latest 10-Q, current reports and proxy.Annual reportFY2025 Form 10-K2026-03-16 · Business model, BOT/BAL, clinical data summaries, FDA history, access programs, Zydus, portfolio, liquidity and FY2025 financials.Quarterly reportQ1 2026 Form 10-Q2026-05-11 · Q1 financial statements, cash, debt, accounts payable, going-concern language, Zydus accounting, operating cash flow and legal updates.Earnings releaseQ1 2026 earnings release2026-05-11 · Phase 3 enrollment, authorized access, Zydus, Q1 revenue, cash payments, SEC investigation update and strategic priorities.Earnings releaseFY2025 and Q4 2025 earnings release2026-03-16 · FY2025 access revenue, BATTMAN status, France AAC expansion and 2025 financial highlights.Proxy statement2026 proxy statement2026-04-30 · Governance, ownership, equity plan increase, option exchange proposal and management stock compensation.Government clinical-trial registryBATTMAN ClinicalTrials.gov record2026-05-14 · Recruiting status, Phase 3 classification, enrollment and completion timing for NCT07152821.Regulator sourceFDA fruquintinib approval notice2023-11-08 · Later-line metastatic colorectal cancer competitive context.Regulator sourceFDA LONSURF plus bevacizumab approval notice2023-08-02 · Previously treated metastatic colorectal cancer competitive context.